[Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai].
BACKGROUND
To elucidate relationship between amino acid sequence of non-structural protein 5A (NS5A) and outcome of HCV (1 b) patients after interferon (IFNa) therapy.


METHODS
Sera of 24 patients were collected before, during and after IFNa therapy. Pretreatment RNA levels and the sequences of HCV NS5A interferon sensitivity determining region (ISDR) were determined. NS5A full-length sequences of 5 HCV isolates from 3 patients with different response types were also analyzed. Phylogenetic tree analysis and protein secondary structure prediction were undertaken.


RESULTS
Pretreatment RNA levels of sustained response group were significantly lower than that of non-response group and relapse group (4.50X104 copies/ml versus 1.82X107 copies/ml, P < 0.01).ISDR sequences of NS5A from pretreatment sera were compared with HCV-J strain (prototype). Thirteen of 24 isolates were wild type,11 of 24 were intermediate type and none of them was mutant type. 3 of 6 sustained responders were infected with wild-type isolates, the rest with intermediate type isolates. Phylogenetic tree based on NS5A full-length sequences classified 5 isolates with 3 different response types into 3 groups. Non-response isolates belonged to the same group as HCV-J. Secondary structure prediction of 5 isolates revealed significant differences existing in 2 255- 2 289. This region was partly overlapped with PKR-binding domain.


CONCLUSIONS
Low HCV RNA levels in serum are associated with favorable outcome of IFNa therapy. ISDR sequence alone could not predict outcome of IFN treatment. Combination of determination of HCV RNA levels in serum with sequence analysis of PKR-binding domain may be helpful in predicting the efficacy of IFN therapy.
Hu
Yunwen
Y
Department of Molecular Virology, Medical Center of Fudan University, Shanghai 200032, China.
Tang
Meifang
M
Jiang
Weilun
W
Wu
Ying
Y
Yuan
Zhenghong
Z
Wen
Yumei
Y
D000595:Amino Acid Sequence; D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D017361:Viral Nonstructural Proteins / Q000235:genetics*
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D017361:Viral Nonstructural Proteins; C118139:p58 protein, classical swine fever virus